Insys Therapeutics (INSY) : Traders are bullish on Insys Therapeutics (INSY) as it has outperformed the S&P 500 by a wide margin of 21.38% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 4.2%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 4.26% in the last 1 week, and is up 22.63% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 12.02% and the 50-Day Moving Average is 21.7%. Insys Therapeutics (NASDAQ:INSY): On Fridays trading session , Opening price of the stock was $18.39 with an intraday high of $18.8. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $18.18. However, the stock managed to close at $18.37, a loss of 0.92% for the day. On the previous day, the stock had closed at $18.54. The total traded volume of the day was 812,077 shares.
The company Insiders own 69.2% of Insys Therapeutics shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -99.98% . Institutional Investors own 51.68% of Insys Therapeutics shares. During last six month period, the net percent change held by insiders has seen a change of -24.32%. Also, In a research note released to the investors, Jefferies maintains its rating on Insys Therapeutics (NASDAQ:INSY).The analysts at the brokerage house have a current rating of Buy on the shares. In a recent information released to the investors, Jefferies raises the new price target from $17 per share to $22 per share. The rating by the firm was issued on August 4, 2016.
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company has two marketed products: Subsys, a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment of chemotherapy-induced nausea and vomiting (CINV), and anorexia associated with weight loss in patients with AIDS. The Companys lead product candidate is Dronabinol oral solution, an orally administered liquid formulation of dronabinol. Dronabinol oral solution has demonstrated more rapidly detectable blood levels and a more reliable absorption profile than Marinol in its clinical studies.